Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -40.73% is 52% above its 5-year average of -85.48%, near the high end of its 5-year range (-150.20%–-37.55%).
20.59% above its 12-month average of -51.29%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -3.80%.
RETURN ON ASSETS (ROA)
-40.73%
RETURN ON ASSETS (ROA) AVG TTM
-51.29%
RETURN ON ASSETS (ROA) AVG 3Y
-88.21%
RETURN ON ASSETS (ROA) AVG 5Y
-85.48%
RETURN ON ASSETS (ROA) AVG 10Y
-6545.95%
RETURN ON ASSETS (ROA) AVG 15Y
-146.99%
RETURN ON ASSETS (ROA) AVG 20Y
-296.22%
CURRENT VS TTM AVG
+20.59%
CURRENT VS 3Y AVG
+53.82%
CURRENT VS 5Y AVG
+52.35%
CURRENT VS 10Y AVG
+99.38%
CURRENT VS 15Y AVG
+72.29%
CURRENT VS 20Y AVG
+86.25%
SECTOR MEDIAN · HEALTHCARE
-23.05%
median of 377 covered companies
CURRENT VS SECTOR MEDIAN
-76.70%
vs the sector median at left
ABVC BioPharma, Inc.
Market Cap
$25.48M
Return on Assets (ROA)
-40.73%
TTM Avg
-51.29%
3Y Avg
-88.21%
5Y Avg
-85.48%
Market Cap
$24.44M
Return on Assets (ROA)
-116.81%
TTM Avg
-53.20%
3Y Avg
-39.87%
5Y Avg
-35.95%
Market Cap
$28.43M
Return on Assets (ROA)
-87.08%
TTM Avg
-72.41%
3Y Avg
-58.48%
5Y Avg
-50.84%
Market Cap
$21.90M
Return on Assets (ROA)
-13.57%
TTM Avg
-12.25%
3Y Avg
-12.55%
5Y Avg
-25.19%
Market Cap
$20.93M
Return on Assets (ROA)
-393.39%
TTM Avg
-225.59%
3Y Avg
-343.91%
5Y Avg
-343.91%
Market Cap
$30.65M
Return on Assets (ROA)
-116.76%
TTM Avg
-76.53%
3Y Avg
-78.60%
5Y Avg
-71.54%
Market Cap
$30.92M
Return on Assets (ROA)
-99.62%
TTM Avg
-39.99%
3Y Avg
-67.06%
5Y Avg
188.84%
Market Cap
$31.36M
Return on Assets (ROA)
-39.14%
TTM Avg
-11.59%
3Y Avg
6.23%
5Y Avg
18.56%
Market Cap
$18.82M
Return on Assets (ROA)
-39.68%
TTM Avg
-29.52%
3Y Avg
-26.86%
5Y Avg
-20.28%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| ABVC BioPharma, Inc. (ABVC) | $25.48M | -40.73% | -51.29% | -88.21% | -85.48% |
| Atossa Therapeutics, Inc. (ATOS)vs › | $24.44M | -116.81% | -53.20% | -39.87% | -35.95% |
| aTyr Pharma, Inc. (ATYR)vs › | $28.43M | -87.08% | -72.41% | -58.48% | -50.84% |
| Aytu BioPharma, Inc. (AYTU)vs › | $21.90M | -13.57% | -12.25% | -12.55% | -25.19% |
| Actuate Therapeutics Inc (ACTU)vs › | $20.93M | -393.39% | -225.59% | -343.91% | -343.91% |
| CervoMed Inc. (CRVO)vs › | $30.65M | -116.76% | -76.53% | -78.60% | -71.54% |
| Context Therapeutics Inc. (CNTX)vs › | $30.92M | -99.62% | -39.99% | -67.06% | 188.84% |
| Baird Medical Investment Holdings Limited (BDMD)vs › | $31.36M | -39.14% | -11.59% | 6.23% | 18.56% |
| Cosmos Health Inc. (COSM)vs › | $18.82M | -39.68% | -29.52% | -26.86% | -20.28% |
| Estrella Immunopharma, Inc. (ESLA)vs › | $18.77M | -548.74% | -346.44% | -242.08% | -167.09% |
ROA
-40.7%
ROE
-76.8%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -37.55% |
| 2024-12-31 | -65.03% |
| 2023-12-31 | -100.05% |
| 2022-12-31 | -150.20% |
| 2021-12-31 | -93.73% |
| 2020-12-31 | -66.30% |
| 2019-12-31 | -52.57% |
| 2018-12-31 | -5791.22% |
| 2017-12-31 | -64.24% |
| 2016-09-30 | -59038.56% |
| 2015-09-30 | -462.57% |
| 2014-09-30 | -37.31% |
| 2013-09-30 | -97.58% |
| 2012-09-30 | -353.80% |
| 2011-12-15 | -329.90% |
| 2010-09-30 | -646.76% |
| 2009-09-30 | -1000.09% |
| 2008-09-30 | -450.79% |
| 2007-09-30 | -386.25% |
| 2006-12-31 | -741.22% |
| 2005-12-31 | -492.21% |
| 2004-12-31 | 2.81% |
| 2003-12-31 | -23.06% |
| 2002-12-31 | -50.00% |
